To include your compound in the COVID-19 Resource Center, submit it here.

FDA reviewers say Natpara is effective

NPS Pharmaceuticals Inc. (NASDAQ:NPSP) stock jumped $6.47 (25%) to $32.24 on Wednesday after FDA reviewers concluded that once-daily subcutaneous injections of Natpara reduced the need for calcium and vitamin

Read the full 293 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE